Harvard Bioscience Balance Sheet Health
Financial Health criteria checks 5/6
Harvard Bioscience has a total shareholder equity of $73.1M and total debt of $36.6M, which brings its debt-to-equity ratio to 50%. Its total assets and total liabilities are $137.4M and $64.3M respectively. Harvard Bioscience's EBIT is $2.5M making its interest coverage ratio 0.7. It has cash and short-term investments of $4.3M.
Key information
50.0%
Debt to equity ratio
US$36.56m
Debt
Interest coverage ratio | 0.7x |
Cash | US$4.28m |
Equity | US$73.07m |
Total liabilities | US$64.29m |
Total assets | US$137.37m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: HBI's short term assets ($49.0M) exceed its short term liabilities ($26.5M).
Long Term Liabilities: HBI's short term assets ($49.0M) exceed its long term liabilities ($37.8M).
Debt to Equity History and Analysis
Debt Level: HBI's net debt to equity ratio (44.2%) is considered high.
Reducing Debt: HBI's debt to equity ratio has reduced from 73.7% to 50% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable HBI has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: HBI is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 8.4% per year.